Table II.
Clinical characteristics of the nine serum samples for western blotting verification.
| No. | Source of serum | Gender | Age (years) | HBsAg | HBsAb | HBeAg | HBeAb | HBcAb | AST (14.5–40.0 U/l) | ALT (3–35 U/l) | TBIL (4.0–23.9 μmol/l) | PT (11.0–14.5 sec) | HBV DNA (IU/ml) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Healthy control | Male | 36 | − | + | − | − | − | 21.0 | 31.0 | 13.8 | 12.3 | <100 |
| 2 | Healthy control | Male | 30 | − | + | − | − | − | 15.0 | 24.0 | 20.1 | 11.1 | <100 |
| 3 | Healthy control | Male | 30 | − | + | − | − | − | 19.2 | 28.6 | 15.6 | 12.8 | <100 |
| 4 | CHB patient | Male | 41 | + | − | + | − | + | 32.0 | 75.4 | 20.5 | 11.3 | 1.88×106 |
| 5 | CHB patient | Male | 31 | + | − | + | − | + | 45.0 | 47.0 | 19.7 | 14.5 | 7.24×106 |
| 6 | CHB patient | Male | 37 | + | − | + | − | + | 36.0 | 41.0 | 23.6 | 11.9 | 3.22×106 |
| 7 | HBV-induced ACLF patient | Male | 21 | + | − | + | − | + | 104.5 | 68.0 | 278.9 | 27.3 | 5.66×106 |
| 8 | HBV-induced ACLF patient | Male | 37 | + | − | + | − | + | 67.0 | 54.0 | 342.1 | 29.7 | 6.58×106 |
| 9 | HBV-induced ACLF patient | Male | 43 | + | − | − | + | + | 36.0 | 78.0 | 521.4 | 31.5 | 7.33×105 |
HBsAg, hepatitis B surface antigen; HBsAb, hepatitis B surface antibody; HBeAg, hepatitis B e antigen; HBeAb, hepatitis B e antibody; HBcAg, hepatitis B core antigen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TBIL, total bilirubin; PT, prothrombin time; HBV, hepatitis B virus; CHB, chronic hepatitis B; ACLF, acute-on-chronic liver failure.